are pharmacies still compound semaglutide Luxury Guide,semaglutide and tirzepatide shortages are officially over

The landscape surrounding compounded semaglutide has been dynamic, with significant shifts in how pharmacies can and still produce these medications. For those seeking compounded versions of popular GLP-1 agonists like Ozempic and Wegovy, understanding the current regulatory environment is crucial. The question of are pharmacies still compounding semaglutide has a nuanced answer, influenced by recent FDA actions and the resolution of drug shortages.

Historically, compounding pharmacies played a vital role in providing alternative formulations of medications when brand-name drugs faced national shortages. This was particularly true for semaglutide and tirzepatide, which experienced significant demand and subsequent supply chain disruptions. Pharmacies and other facilities were able to mass compounding semaglutide and its counterparts, often creating versions with added ingredients like vitamin B12 (cyanocobalamin) or offering non-standard doses not commercially available. Yet compounding pharmacies continued to produce these drugs by creating custom versions that contain certain additives and supplements.

However, the situation has evolved. The semaglutide and tirzepatide shortages are officially over. The U.S. Food and Drug Administration (FDA) has officially declared the semaglutide shortage ended, which has had a direct impact on the ability of compounders to manufacture these drugs. Under U.S. law, a brand-name drug on the FDA shortage list can be made available by compounding pharmacies, even if still under patent protection. With the shortage resolved, this provision no longer applies in the same way. As of February 2025, semaglutide was removed from the list, and compounding pharmacies must stop producing their own versions of the drug. Consequently, many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide.

This regulatory shift means that compounded semaglutide is now subject to stricter guidelines. While compounding pharmacies can still make compounded semaglutide under specific circumstances, such as for individual patient prescriptions that meet certain criteria or for use in 503B outsourcing facilities under specific conditions, the era of widespread mass compounding for general availability has largely concluded. The FDA's clarification on policies for compounders indicates that while some forms of compounding may persist, the broad production that occurred during the shortage is being phased out.

The FDA's stance emphasizes that compounded semaglutide products are not FDA-reviewed and can pose risks. Many compounded versions have been found to be unsafe, misused, or mislabeled. The FDA-approved versions, such as Wegovy® and Ozempic®, are now fully available nationwide. This availability makes it illegal to make or sell compounded "semaglutide" except for rare circumstances. Furthermore, semaglutide from compounding pharmacies frequently lacks Good Manufacturing Practice (GMP) standards, raising concerns about product quality and safety.

Despite the FDA's ruling, some compounded GLP-1s are still for sale on direct-to-patient platforms. Online pharmacies are using a loophole to continue selling weight loss drugs that are modeled on Ozempic and Mounjaro, despite new FDA regulations. However, patients seeking these alternatives should exercise extreme caution. These compounded drugs are not FDA approved, and their efficacy and safety can be questionable. The practice of compounding is intended for unique patient needs not met by commercially available drugs, not as a widespread alternative to FDA-approved medications.

For patients who previously relied on compounded semaglutide for weight loss, the end of the shortage and the new regulations present challenges. It is important to consult with a healthcare provider to discuss available FDA-approved options and understand the risks and benefits associated with any medication, whether brand-name or compounded. The availability of semaglutide and tirzepatide in their approved forms means that the need for widespread compounding has diminished, and patients should prioritize treatments that have undergone rigorous FDA review for safety and efficacy. The focus has shifted from the widespread availability of compounded products to ensuring access to the FDA-approved medications.